These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
492 related articles for article (PubMed ID: 36853018)
21. Integration analysis of single-cell and spatial transcriptomics reveal the cellular heterogeneity landscape in glioblastoma and establish a polygenic risk model. Liu Y; Wu Z; Feng Y; Gao J; Wang B; Lian C; Diao B Front Oncol; 2023; 13():1109037. PubMed ID: 37397378 [TBL] [Abstract][Full Text] [Related]
22. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Gill BJ; Pisapia DJ; Malone HR; Goldstein H; Lei L; Sonabend A; Yun J; Samanamud J; Sims JS; Banu M; Dovas A; Teich AF; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Sims PA; Canoll P Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12550-5. PubMed ID: 25114226 [TBL] [Abstract][Full Text] [Related]
23. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development. Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D Front Immunol; 2022; 13():773264. PubMed ID: 35185876 [TBL] [Abstract][Full Text] [Related]
24. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment. Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051 [TBL] [Abstract][Full Text] [Related]
25. Single-cell atlas reveals the immunosuppressive microenvironment and Treg cells landscapes in recurrent Glioblastoma. Wang X; Ge Y; Hou Y; Wang X; Yan Z; Li Y; Dong L; She L; Tang C; Wei M; Zhang H Cancer Gene Ther; 2024 May; 31(5):790-801. PubMed ID: 38429367 [TBL] [Abstract][Full Text] [Related]
26. The Many Facets of Therapy Resistance and Tumor Recurrence in Glioblastoma. Goenka A; Tiek D; Song X; Huang T; Hu B; Cheng SY Cells; 2021 Feb; 10(3):. PubMed ID: 33668200 [TBL] [Abstract][Full Text] [Related]
27. Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. Shen Y; Grisdale CJ; Islam SA; Bose P; Lever J; Zhao EY; Grinshtein N; Ma Y; Mungall AJ; Moore RA; Lun X; Senger DL; Robbins SM; Wang AY; MacIsaac JL; Kobor MS; Luchman HA; Weiss S; Chan JA; Blough MD; Kaplan DR; Cairncross JG; Marra MA; Jones SJM Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19098-19108. PubMed ID: 31471491 [TBL] [Abstract][Full Text] [Related]
28. Immune Microenvironment in Glioblastoma Subtypes. Chen Z; Hambardzumyan D Front Immunol; 2018; 9():1004. PubMed ID: 29867979 [TBL] [Abstract][Full Text] [Related]
29. Molecular Markers of Therapy-Resistant Glioblastoma and Potential Strategy to Combat Resistance. Nguyen HS; Shabani S; Awad AJ; Kaushal M; Doan N Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899215 [TBL] [Abstract][Full Text] [Related]
30. Perivascular signals alter global gene expression profile of glioblastoma and response to temozolomide in a gelatin hydrogel. Ngo MT; Harley BAC Biomaterials; 2019 Apr; 198():122-134. PubMed ID: 29941152 [TBL] [Abstract][Full Text] [Related]
32. Dynamic expression of 11 miRNAs in 83 consecutive primary and corresponding recurrent glioblastoma: correlation to treatment, time to recurrence, overall survival and MGMT methylation status. Matos B; Bostjancic E; Matjasic A; Popovic M; Glavac D Radiol Oncol; 2018 Nov; 52(4):422-432. PubMed ID: 30511935 [TBL] [Abstract][Full Text] [Related]
33. Gene signatures of quiescent glioblastoma cells reveal mesenchymal shift and interactions with niche microenvironment. Tejero R; Huang Y; Katsyv I; Kluge M; Lin JY; Tome-Garcia J; Daviaud N; Wang Y; Zhang B; Tsankova NM; Friedel CC; Zou H; Friedel RH EBioMedicine; 2019 Apr; 42():252-269. PubMed ID: 30952620 [TBL] [Abstract][Full Text] [Related]
34. Tumor Niches: Perspectives for Targeted Therapies in Glioblastoma. Srivastava R; Dodda M; Zou H; Li X; Hu B Antioxid Redox Signal; 2023 Nov; 39(13-15):904-922. PubMed ID: 37166370 [No Abstract] [Full Text] [Related]
35. Tracking intratumoral heterogeneity in glioblastoma via regularized classification of single-cell RNA-Seq data. Lopes MB; Vinga S BMC Bioinformatics; 2020 Feb; 21(1):59. PubMed ID: 32070274 [TBL] [Abstract][Full Text] [Related]
37. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme. Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071 [TBL] [Abstract][Full Text] [Related]
38. An Integrated Bioinformatics Study of a Novel Niclosamide Derivative, NSC765689, a Potential Mokgautsi N; Wen YT; Lawal B; Khedkar H; Sumitra MR; Wu ATH; Huang HS Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33671112 [TBL] [Abstract][Full Text] [Related]
39. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. Song WS; Yang YP; Huang CS; Lu KH; Liu WH; Wu WW; Lee YY; Lo WL; Lee SD; Chen YW; Huang PI; Chen MT J Chin Med Assoc; 2016 Oct; 79(10):538-45. PubMed ID: 27530866 [TBL] [Abstract][Full Text] [Related]
40. Proteomic analysis predicts anti-angiogenic resistance in recurred glioblastoma. Jeon H; Byun J; Kang H; Kim K; Lee E; Kim JH; Hong CK; Song SW; Kim YH; Chong S; Kim JH; Nam SJ; Park JE; Lee S J Transl Med; 2023 Feb; 21(1):69. PubMed ID: 36732815 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]